StreetInsider.com News Articles

Vera Therapeutics (VERA) Reiterated at Overweight by Cantor Fitzgerald

Fri, 23 Oct 2026 07:40:46 -0400

Cantor Fitzgerald analyst Pete Stavropoulos reiterated an Overweight rating and $100.00 price target on Vera Therapeutics (NASDAQ: VERA).

The analyst commented, "VERA took center stage at the opening plenary session, with P3 ORIGIN 3 efficacy analysis of Trutakna (atacicept; BAFF/APRIL inh) in IgA nephropathy (IgAN), alongside a NEJM publication (here), and hosted a webinar this afternoon. The room was packed with nephrologists and there was great enthusiasm for the B cell modulator class. VERA’s presentation covered 2-yr kidney function data, stabilization of eGFR, subgroup analyses, and a 76% reduction in the risk of kidney disease progression. ASN and NEJM could influence

Vera Therapeutics ORIGIN 3 trial meets all endpoints for IgAN drug

Thu, 22 Oct 2026 10:09:06 -0400

Vera Therapeutics (Nasdaq: VERA) announced that the final efficacy analysis of its ORIGIN 3 trial for TRUTAKNA (atacicept-vymj) in adults with primary IgA nephropathy (IgAN) met statistical significance across all prespecified endpoints. The results were presented at the American Society of Nephrology Kidney Week 2026 and simultaneously published in the New England Journal of Medicine.

The trial, which enrolled 428 patients split evenly between TRUTAKNA and placebo groups, achieved its primary endpoint of statistically significant proteinuria reduction at 36 weeks. Additional endpoints showing statistical significance included estimated glomerular filtration rate (eGFR) change from baseline, annualized eGFR slope, and a composite measure

Vera Therapeutics ORIGIN 3 trial meets all endpoints for IgAN drug

Thu, 22 Oct 2026 10:09:06 -0400

Vera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Presented at ASN Kidney Week 2026 and Published in the New England Journal of M

Thu, 22 Oct 2026 10:05:00 -0400

TRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, achieved statistical significance in all prespecified endpoints, including eGFR change from baseline and annualized slope, and risk reduction in composite kidney disease progression events.
Favorable safety profile, and generally comparable to placebo.
Plan to submit supplemental BLA to the U.S. FDA in Q4 2026 for full approval expected in 2027.
Investor webcast is scheduled for October 22 at 4:30 pm EDT.

BRISBANE, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that the final

Vera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Presented at ASN Kidney Week 2026 and Published in the New England Journal of M

Thu, 22 Oct 2026 10:05:00 -0400

TRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, achieved statistical significance in all prespecified endpoints, including eGFR change from baseline and annualized slope, and risk reduction in composite kidney disease progression events.
Favorable safety profile, and generally comparable to placebo.
Plan to submit supplemental BLA to the U.S. FDA in Q4 2026 for full approval expected in 2027.
Investor webcast is scheduled for October 22 at 4:30 pm EDT.

BRISBANE, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that the final

Vera Therapeutics to Host ASN Kidney Week Investor Webcast and Third Quarter 2026 Financial Results Conference Webcast

Tue, 20 Oct 2026 08:00:00 -0400

Investor webcast at 4:30 p.m. ET on October 22 to discuss ORIGIN 3 final efficacy results for TRUTAKNA™ (atacicept-vymj) featured in a late-breaking oral presentation during the opening plenary session of ASN Kidney Week 2026
Q3 2026 financial results investor webcast scheduled at 4:30 p.m. ET on November 5

BRISBANE, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that it will host two upcoming investor webcasts to discuss ORIGIN 3 final efficacy results as presented at the American Society of Nephrology (ASN) Kidney Week

Vera Therapeutics to Host ASN Kidney Week Investor Webcast and Third Quarter 2026 Financial Results Conference Webcast

Tue, 20 Oct 2026 08:00:00 -0400

Investor webcast at 4:30 p.m. ET on October 22 to discuss ORIGIN 3 final efficacy results for TRUTAKNA™ (atacicept-vymj) featured in a late-breaking oral presentation during the opening plenary session of ASN Kidney Week 2026
Q3 2026 financial results investor webcast scheduled at 4:30 p.m. ET on November 5

Leerink Starts Vera Therapeutics (VERA) at Market Perform

Mon, 12 Oct 2026 06:27:50 -0400

Leerink analyst Will Soghikian initiates coverage on Vera Therapeutics (NASDAQ: VERA) with a Market Perform rating and a price target of $34.00.

For an analyst ratings summary and ratings history on Vera Therapeutics click here. For more ratings news on Vera Therapeutics click here.

Shares of Vera Therapeutics closed at $29.88 yesterday.

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 02 Oct 2026 16:05:00 -0400

BRISBANE, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on September 29, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 16,700 shares of Class A common stock and restricted stock units (RSUs) underlying 8,350 shares of Class A common stock to five (5) new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Each

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 02 Oct 2026 16:05:00 -0400

Each

Vera Therapeutics to present ORIGIN 3 trial data at ASN Kidney Week

Fri, 02 Oct 2026 09:25:48 -0400

Vera Therapeutics (NASDAQ: VERA) announced that final efficacy data from its ORIGIN 3 trial of TRUTAKNA (atacicept-vymj) in IgA nephropathy (IgAN) will be presented as a featured late-breaking oral presentation at the opening plenary session of the American Society of Nephrology (ASN) Kidney Week 2026, scheduled for October 22–25 in Denver, Colorado.

The ORIGIN 3 presentation, abstract number TH-OR109, will be delivered by Jonathan Barratt, PhD, FRCP, Mayer Professor of Renal Medicine at the University of Leicester, on October 22 from 9:05 to 9:12 AM MDT. The data will also appear as a late-breaking research poster the same day.

In total, five

Vera Therapeutics to present ORIGIN 3 trial data at ASN Kidney Week

Fri, 02 Oct 2026 09:25:48 -0400

In total, five

Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN

Fri, 02 Oct 2026 09:24:00 -0400

BRISBANE, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that there will be multiple presentations at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, from October 22 to 25. The final efficacy analysis of the ORIGIN 3 trial of TRUTAKNA in IgA nephropathy (IgAN) will be a featured late-breaking oral presentation during the opening plenary session and also a late-breaking research poster. In addition, interim results from the adult IgAN and primary membranous nephropathy (pMN) cohorts in PIONEER, a Phase 2 basket trial of

Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN

Fri, 02 Oct 2026 09:24:00 -0400

Form 4 Vera Therapeutics, Inc. For: Sep 15 Filed by: Fordyce Marshall

Thu, 17 Sep 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20260917/27076216.html

TD Cowen Reiterates Buy Rating on Vera Therapeutics (VERA)

Tue, 15 Sep 2026 10:46:19 -0400

TD Cowen analyst Ritu Baral reiterated a Buy rating and $78.00 price target on Vera Therapeutics (NASDAQ: VERA).

They analyst comments "Today's 2 yr ORIGIN3 dataset further underscores that Trutakna treatment meaningfully improves IgAN disease progression, likely providing effective kidney function stabilization and driving improvements in kidney outcomes. The annualized eGFR slope delta of +5.0 mL/min/year vs PBO is among the most compelling kidney function datasets generated in a Ph3 IgAN trial, numerically superior than +4.5 mL/min/year PBO-adjusted benefit for Voyxact, a difference that we acknowledge could fall within the variability of the measure. Importantly, Trutakna drove a 2-year annualized eGFR

Raymond James Reiterates Strong Buy Rating on Vera Therapeutics (VERA)

Tue, 15 Sep 2026 09:58:54 -0400

Raymond James analyst Ryan Deschner reiterated a Strong Buy rating and $84.00 price target on Vera Therapeutics (NASDAQ: VERA)

The analyst comments "Vera reported the final efficacy analysis (n=428) for their pivotal ORIGIN 3 study needed for full approval of Trutakna in IgAN, which included 104-week annualized eGFR slope of -0.6 mL/min/ SSA/yr (similar to the 2-year eGFR in Phase 2b and within the KDIGO guidelines), a statistically significant kidney composite endpoint (HR 0.24, p<0.0001), and zero patients experiencing dialysis ≥30 days/transplant/death vs. eight in the placebo arm through 104 weeks. Vera also reported 350 patient start forms 10 weeks into

Form 8-K Vera Therapeutics, Inc. For: Sep 15

Tue, 15 Sep 2026 06:46:00 -0400

si-local-file:///var/storage/secattach/20260915/27060826.html

Vera Therapeutics drug meets all endpoints in two-year IgAN trial

Tue, 15 Sep 2026 06:30:43 -0400

Vera Therapeutics (Nasdaq: VERA) announced that its drug TRUTAKNA (atacicept-vymj) met all prespecified endpoints in the final efficacy analysis of the ORIGIN 3 trial in adults with primary IgA nephropathy (IgAN) at risk for disease progression, according to a company press release.

The analysis of 428 patients showed a mean eGFR change from baseline of -0.1 in the TRUTAKNA group versus -5.7 in the placebo group at 52 weeks, a treatment effect of 5.6 (p<0.0001). Over 104 weeks, the annualized eGFR slope was -0.6 for TRUTAKNA versus -5.6 for placebo, a treatment effect of 5.0 (p<0.0001).

For composite kidney disease progression events

Vera Therapeutics drug meets all endpoints in two-year IgAN trial

Tue, 15 Sep 2026 06:30:43 -0400

For composite kidney disease progression events

Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy

Tue, 15 Sep 2026 06:30:00 -0400

TRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, met all prespecified endpoints, including unprecedented placebo-adjusted estimated glomerular filtration rate (eGFR) and composite kidney disease progression benefits.
Favorable safety profile, and generally comparable to placebo.
Strong commercial launch momentum with over 350 patient start forms generated in the first ten weeks.
Plan to submit supplemental BLA to the U.S. Food and Drug Administration (FDA) for full approval in Q4 2026.

BRISBANE, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that

Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy

Tue, 15 Sep 2026 06:30:00 -0400

TRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, met all prespecified endpoints, including unprecedented placebo-adjusted estimated glomerular filtration rate (eGFR) and composite kidney disease progression benefits.
Favorable safety profile, and generally comparable to placebo.
Strong commercial launch momentum with over 350 patient start forms generated in the first ten weeks.
Plan to submit supplemental BLA to the U.S. Food and Drug Administration (FDA) for full approval in Q4 2026.

BRISBANE, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that

Form 4 Vera Therapeutics, Inc. For: Sep 11 Filed by: Young Joseph R

Mon, 14 Sep 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260914/27058763.html

Vera Therapeutics (VERA) PT Raised to $83 at JPMorgan

Tue, 08 Sep 2026 08:48:58 -0400

JPMorgan analyst Anupam Rama raised the price target on Vera Therapeutics (NASDAQ: VERA) to $83.00 (from $76.00) while maintaining a Overweight rating.

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 04 Sep 2026 16:05:00 -0400

BRISBANE, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on September 1, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 61,500 shares of Class A common stock and restricted stock units (RSUs) underlying 30,750 shares of Class A common stock to six (6) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing